Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for ER-positive breast cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Evolving Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer

MODULE 2: Current Management of ER-Positive Metastatic Breast Cancer

MODULE 3: Promising Investigational Strategies for Patients with ER-Positive Metastatic Breast Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

• Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for patients with newly diagnosed ER-positive, HER2-negative, lymph node-negative or node-positive breast cancer.
• Recall available Phase III data documenting the benefit of abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative localized breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
• Individualize the selection and sequence of systemic therapy for newly diagnosed ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease), prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy) and patient preference and tolerability for specific side effects.
• Appraise available research data with commercially available CDK4/6 inhibitors for the treatment of ER-positive mBC, and optimally incorporate these agents into patient care.
• Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations in individuals with ER-positive mBC, and understand the FDA-approved indication for alpelisib in combination with fulvestrant in order to optimally employ this approach for postmenopausal patients with ER-positive, HER2-negative, PIK3CA-mutated disease.
• Recall ongoing clinical research evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Goetz — Consulting Agreements (Honoraria to Institution): AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Biovica, Blueprint Medicines, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc, Sermonix Pharmaceuticals; Contracted Research (to Institution): Lilly, Pfizer Inc, Sermonix Pharmaceuticals. Dr Jhaveri — Advisory Committee: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Jounce Therapeutics, Novartis, Pfizer Inc, Spectrum Pharmaceuticals Inc, Sun Pharma Advanced Research Company, Synthon, Taiho Oncology Inc; Contracted Research: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Lilly, Merck, Novartis, Novita Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Zymeworks. Dr Kaklamani — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Sanofi Genzyme; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc. Dr Kalinsky — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Cyclacel Pharmaceuticals Inc, Eisai Inc, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Seagen Inc; Speakers Bureau: Genentech, a member of the Roche Group, Immunomedics Inc. Dr Mayer — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cyclacel Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, Pfizer Inc. Dr O’Regan — Advisory Committee and Consulting Agreements: bioTheranostics Inc, Cyclacel Pharmaceuticals Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Contracted Research: Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Immunomedics Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Exact Sciences Inc, Novartis and Sanofi Genzyme.